Multiple Sclerosis Clinical Trial
Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis
Summary
The primary goal of this study is to assess the efficacy of bazedoxifene (BZA) as remyelinating agent in patients with relapsing-remitting multiple sclerosis (RRMS).
The investigators will utilize electrophysiologic techniques and magnetic resonance imaging to quantify the effect of treatment in 50 women over the course of 6 months.
Participants may remain on their standard disease modifying treatment during the course of the trial but may not concurrently participate in any other investigational new drug research study.
Full Description
Multiple Sclerosis (MS) is a chronic neurologic disorder characterized by the loss of myelin, which results in disruption of nerve signal, damage to axons, and, ultimately, neurodegeneration. In order to treat MS, new methods for promoting repair (remyelination) are sorely needed.
There is a strong preclinical (including EAE) and epidemiologic rationale for investigating the remyelinating potential of estrogenic compounds, including evidence of endogenous (puberty, postpartum periods) and exogenous hormonal influences on MS risk and course. MS affects 3 times more women than men, and disease course in women appears overall less aggressive (on MRI, fewer T2-hyperintense demyelinated lesions develop into axonal destruction visualized as hypointense T1 "black holes").
Bazedoxifene (BZA), a third-generation SERM with extensive safety data in humans, was identified in a novel high-throughput screen (BIMA screen) for compounds capable of promoting remyelination. Subsequent analysis validated BZA's remyelinating effect in vitro and in vivo following demyelinating insult. Given strong pre-clinical support for BZA's remyelinating potential, and the clinical success of other compounds identified using the BIMA screen (Green et al., 2017), the investigators will investigate the use of BZA as a remyelinating therapy in patients with MS.
Eligibility Criteria
Inclusion Criteria:
Women aged 45-65 or 40+ post-menopausal.
Documentation of a clinically definite diagnosis of relapsing-remitting MS
Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.
Latency delay > 118 milliseconds on baseline full-field transient pattern reversal VEP in at least one eye (electrophysiological evidence of demyelination)
RNFL > 70 microns on SD-OCT in the same eye meeting criteria for latency delay (sufficient axons)
Stable immunomodulatory therapy - no switch or planned switch in > 6 months and no change in doses in 30 days prior to screening
Use of contraceptive method with ≤1% failure rate during period of trial if premenopausal
Understand and sign informed consent.
EDSS 0-6.0 (inclusive)
Exclusion Criteria:
Multiple Sclerosis disease duration > 25 years
Optic neuritis in prior 6 months
Known optic neuritis in involved eye ≥ 10 years ago
Major ophthalmologic disease/Concomitant ophthalmologic disorders (e.g. diabetes, macular degeneration, glaucoma, severe myopia, etc.).
Myopia > -7 Diopters (severe myopia)
Disc hemorrhages in qualifying eye
No light perception in qualifying eye
Simultaneous bilateral optic neuritis
Cotton wool spots in qualifying eye
Macular star in qualifying eye
History of significant cardiac conduction block
History of cancer (except non-melanoma skin cancer)
Suicidal ideation or behavior in 6 months prior to baseline
Pregnancy, breastfeeding, or planning to become pregnant
Included with other study protocol simultaneously without prior approval
Concomitant or prior use of any other putative remyelinating therapy as determined by investigator, including but not limited to Clemastine, Duavee, and Tamoxifen.
Serum creatinine > 1.5mg/dL; AST, ALT, or alkaline phosphatase > 2 times the upper limit of normal
History of drug or alcohol abuse within the past year
Untreated B12 deficiency (as determined by B12 serological assessments and metabolites including methylmalonic acid [MMA] and homocysteine) or untreated hypothyroidism
Clinically significant cardiac, metabolic, hematologic, hepatic, immunologic, urologic, endocrinologic, neurologic, pulmonary, psychiatric, dermatologic, allergic, renal or other major diseases that in the PI's judgement may affect interpretation of study results or patient safety.
History of or presence of clinically significant medical illness or laboratory abnormality that, in the opinion of the investigator would preclude participation in the study.
Patients whose lack of mobility exposes them to an increased risk of venous thromboembolism
Patients with undiagnosed uterine bleeding
Patients with unknown, suspected or past history of breast cancer
Patients with known or suspected estrogen-dependent neoplasia
Patients with active or a past history of venous thromboembolism
Patients with active or a past history of arterial thromboembolism
Patients with known protein C, protein S, or antithrombin deficiency or other known thrombophilic disorders
Patients with hypersensitivity (angioedema, anaphylaxis) to estrogens, bazedoxifene, or any ingredients
Patients with known hepatic impairment or disease
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
San Francisco California, 94158, United States More Info
Principal Investigator
How clear is this clinincal trial information?